ResMed (RMD) Announces Earnings Results

ResMed (NYSE:RMD) issued its earnings results on Monday. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.22, Bloomberg Earnings reports. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The business had revenue of $601.27 million for the quarter, compared to analysts’ expectations of $583.77 million. During the same quarter in the previous year, the firm posted $0.73 EPS. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year.

ResMed (NYSE RMD) traded down $1.17 during trading on Monday, hitting $87.51. 1,087,658 shares of the stock traded hands, compared to its average volume of 518,377. The company has a market capitalization of $12,584.04, a PE ratio of 35.43, a P/E/G ratio of 2.24 and a beta of 0.79. ResMed has a 52-week low of $62.64 and a 52-week high of $89.72. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50.

In related news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $84.99, for a total value of $106,237.50. Following the transaction, the chief financial officer now owns 78,322 shares of the company’s stock, valued at $6,656,586.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider James Hollingshead sold 600 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total value of $50,976.00. Following the completion of the transaction, the insider now directly owns 62,602 shares in the company, valued at approximately $5,318,665.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 158,929 shares of company stock worth $13,181,009. Insiders own 1.77% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Northland Securities reissued a “sell” rating and set a $55.00 target price on shares of ResMed in a report on Friday, October 27th. Jefferies Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of ResMed in a report on Thursday, October 12th. BMO Capital Markets upped their price target on shares of ResMed to $82.00 and gave the stock a “market perform” rating in a report on Tuesday, December 12th. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a report on Monday, October 30th. Finally, Barclays upped their price target on shares of ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a report on Monday, September 25th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $70.57.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with's FREE daily email newsletter.

Leave a Reply